{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:41:18Z","timestamp":1761100878161},"reference-count":154,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T00:00:00Z","timestamp":1180656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2007,6]]},"DOI":"10.1016\/j.beha.2006.10.003","type":"journal-article","created":{"date-parts":[[2007,4,20]],"date-time":"2007-04-20T16:07:35Z","timestamp":1177085255000},"page":"125-154","source":"Crossref","is-referenced-by-count":24,"title":["Risk assessment in haemotopoietic stem cell transplantation: Disease and disease stage"],"prefix":"10.1016","volume":"20","author":[{"given":"Aristeidis","family":"Chaidos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed","family":"Kanfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2006.10.003_bib1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.beha.2006.10.003_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM200104053441409","article-title":"Editorial: targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Goldman","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-104-2-155","article-title":"Marrow transplantation for the treatment of chronic myelogenous leukemia","volume":"104","author":"Thomas","year":"1986","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib4","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/blood.V82.7.2235.2235","article-title":"Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase","volume":"82","author":"Goldman","year":"1993","journal-title":"Blood"},{"issue":"8378","key":"10.1016\/j.beha.2006.10.003_bib5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(84)92179-2","article-title":"Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia","volume":"1","author":"Speck","year":"1984","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1056\/NEJM198601233140403","article-title":"Bone marrow transplantation for patients with chronic myeloid leukemia","volume":"314","author":"Goldman","year":"1986","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1182\/blood.V81.2.543.543","article-title":"Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program","volume":"81","author":"McGlave","year":"1993","journal-title":"Blood"},{"issue":"supplement 1","key":"10.1016\/j.beha.2006.10.003_bib8","first-page":"170","article-title":"Long term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CMP-CP): the 5 year update from the IRIS study","volume":"91","author":"Guilhot","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2006.10.003_bib9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"supplement 3","key":"10.1016\/j.beha.2006.10.003_bib10","first-page":"S5","article-title":"Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry","volume":"17","author":"Horowitz","year":"1996","journal-title":"Bone Marrow Transplantation"},{"issue":"supplement 3","key":"10.1016\/j.beha.2006.10.003_bib11","first-page":"S1","article-title":"Marrow transplantation for CML: the Seattle experience","volume":"17","author":"Clift","year":"1996","journal-title":"Bone Marrow Transplantation"},{"issue":"9134","key":"10.1016\/j.beha.2006.10.003_bib12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib13","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2002-08-2619","article-title":"HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen","volume":"102","author":"Radich","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib15","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib16","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u2018good-risk\u2019 chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib18","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"Journal of the National Cancer Institute"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1080\/1042819021000006547","article-title":"Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia","volume":"43","author":"Keating","year":"2002","journal-title":"Leukemia & Lymphoma"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib21","first-page":"275","article-title":"Allogeneic bone-marrow transplantation in chronic lymphocytic-leukemia \u2013 17 cases \u2013 report from the Ebmtg","volume":"7","author":"Michallet","year":"1991","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.7326\/0003-4819-124-3-199602010-00005","article-title":"HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia","volume":"124","author":"Michallet","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib23","first-page":"522A","article-title":"Hematopoietic stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL)","volume":"96","author":"Horowitz","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/sj.bmt.1702237","article-title":"Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia","volume":"25","author":"Pavletic","year":"2000","journal-title":"Bone Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib25","first-page":"205A","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): results and prognostic factors for survival after transplantation. Analysis from EBMT registry","volume":"96","author":"Michallet","year":"2000","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/146532402320219736","article-title":"Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation","volume":"4","author":"Khouri","year":"2002","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib27","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.bmt.1703548","article-title":"Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia","volume":"29","author":"Doney","year":"2002","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib28","first-page":"371","article-title":"Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia","volume":"17","author":"Mehta","year":"1996","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib29","first-page":"669","article-title":"Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia","volume":"18","author":"Rondon","year":"1996","journal-title":"Bone Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/sj.bmt.1700850","article-title":"Induction of graft-versus-leukemia effect in a patient with chronic lymphocytic leukemia","volume":"20","author":"deMagalhaesSilverman","year":"1997","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.beha.2006.10.003_bib32","first-page":"S31","article-title":"Prognostic factors for survival after autologous and allogeneic stem cell transplantation for Chronic Lymphocytic Leukemia (CLL): the EBMT experience","volume":"27","author":"Michallet","year":"2001","journal-title":"Bone Marrow Transplantation"},{"issue":"13","key":"10.1016\/j.beha.2006.10.003_bib33","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.beha.2006.10.003_bib34","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1200\/JCO.2005.03.962","article-title":"Unrelated donor marrow transplantation for B-cell chronic lymphocytic leukemia after using myeloablative conditioning: results from the Center for International Blood and Marrow Transplant research","volume":"23","author":"Pavletic","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib35","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/sj.bmt.1702722","article-title":"Reduced-intensity allogeneic stem cell transplantation as salvage treatment for patients with indolent lymphoma or CLL after failure of autologous SCT","volume":"26","author":"Dreger","year":"2000","journal-title":"Bone Marrow Transplantation"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib36","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"issue":"supplement 2","key":"10.1016\/j.beha.2006.10.003_bib38","first-page":"S47","article-title":"Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia","volume":"81","author":"Schetelig","year":"2002","journal-title":"Annals of Hematology"},{"issue":"14","key":"10.1016\/j.beha.2006.10.003_bib39","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib40","first-page":"885","article-title":"Reduced intensity conditioning allogeneic transplant for advanced chronic lymphocytic leukemia","volume":"89","author":"Soligo","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib41","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2005-08-3372","article-title":"Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study","volume":"107","author":"Delgado","year":"2006","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib42","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/sj.leu.2403745","article-title":"Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis","volume":"19","author":"Dreger","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib43","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1182\/blood.V89.7.2311","volume":"89","author":"Hann","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/blood-2002-12-3714","article-title":"Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC\/GIMEMAAML-10 trial","volume":"102","author":"Suciu","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib45","first-page":"2978","article-title":"Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM)","volume":"90","author":"Harousseau","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1200\/JCO.1990.8.2.287","article-title":"Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study","volume":"8","author":"Lowenberg","year":"1990","journal-title":"Journal of Clinical Oncology"},{"issue":"9104","key":"10.1016\/j.beha.2006.10.003_bib47","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(97)09214-3","article-title":"Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"351","author":"Burnett","year":"1998","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.beha.2006.10.003_bib48","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJM199812033392301","article-title":"Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission","volume":"339","author":"Cassileth","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"13","key":"10.1016\/j.beha.2006.10.003_bib49","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib50","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/cncr.20945","article-title":"Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis","volume":"103","author":"Yanada","year":"2005","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib51","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib52","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered","volume":"17","author":"Byrd","year":"1999","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib53","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2002-11-3527","article-title":"Prognosis of inv(16)\/t(16;16) acute myeloid leukemia (AML): a\u00a0survey of 110 cases from the French AML Intergroup","volume":"102","author":"Delaunay","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib54","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2141.2002.03724.x","article-title":"The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial","volume":"118","author":"Burnett","year":"2002","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.bmt.1705265","article-title":"Allogeneic and autologous transplantation for\u00a0haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe","volume":"37","author":"Ljungman","year":"2006","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib56","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.2005.03.127","article-title":"Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group","volume":"23","author":"De Botton","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib57","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/sj.leu.2403078","article-title":"Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease","volume":"17","author":"Lo-Coco","year":"2003","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJM199501263320403","volume":"332","author":"Zittoun","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib59","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1046\/j.1365-2141.1999.01684.x","article-title":"A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties","volume":"107","author":"Wheatley","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib61","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib62","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.bmt.1705038","article-title":"Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?","volume":"36","author":"Song","year":"2005","journal-title":"Bone Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib63","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V80.4.1090.bloodjournal8041090","article-title":"Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy","volume":"80","author":"Biggs","year":"1992","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2003.08.004","article-title":"A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome","volume":"9","author":"Fung","year":"2003","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2141.1999.01713.x","article-title":"Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia","volume":"107","author":"Grigg","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib66","first-page":"415","article-title":"Bone marrow transplantation for primary refractory acute leukaemia","volume":"14","author":"Mehta","year":"1994","journal-title":"Bone Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib67","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib68","first-page":"13","article-title":"Chemotherapy versus transplants for acute myelogenous leukemia in second remission","volume":"10","author":"Gale","year":"1996","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib69","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.1992.10.11.1723","article-title":"Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia","volume":"10","author":"Clift","year":"1992","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/sj.leu.2401668","article-title":"Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities","volume":"14","author":"Kern","year":"2000","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib71","first-page":"998","article-title":"Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia","volume":"89","author":"Ferrara","year":"2004","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib72","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","article-title":"Prognostic index for adult patients with acute myeloid leukemia in first relapse","volume":"23","author":"Breems","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib73","first-page":"522A","article-title":"Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: A survey of the European Blood and Marrow Transplantation Group (EBMT)","volume":"96","author":"Sanz","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib74","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"British Journal of Haematology"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib75","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib76","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2141.1990.tb02558.x","article-title":"Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG)","volume":"74","author":"de Witte","year":"1990","journal-title":"British Journal of Haematology"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib77","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V82.2.677.677","article-title":"Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome","volume":"82","author":"Anderson","year":"1993","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib78","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1182\/blood.V88.1.358.358","article-title":"Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle","volume":"88","author":"Sutton","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V87.1.51.51","article-title":"Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors","volume":"87","author":"Anderson","year":"1996","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib81","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V89.7.2578","article-title":"Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy","volume":"89","author":"Anderson","year":"1997","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib82","first-page":"1085","article-title":"Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia","volume":"84","author":"Witherspoon","year":"1999","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib83","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1046\/j.1365-2141.2000.02200.x","article-title":"Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"110","author":"de Witte","year":"2000","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib84","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1182\/blood.V99.12.4370","article-title":"Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes","volume":"99","author":"Guardiola","year":"2002","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib85","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","article-title":"Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia","volume":"82","author":"Kroger","year":"2003","journal-title":"Annals of Hematology"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib86","first-page":"185A","article-title":"Efficacy of non-myeloablative alloeneic transplant for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD) (Except chronic myelogenous leukemia)","volume":"102","author":"Stuart","year":"2003","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib87","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib88","first-page":"184A","volume":"102","author":"Martino","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib89","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib90","first-page":"637","article-title":"Graft versus leukemia without fatal graft-versus-host disease in AKR mice","volume":"35","author":"Chester","year":"1975","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib91","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-versus-leukemia reactions after bone marrow transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib92","first-page":"453","article-title":"Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival","volume":"7","author":"Doney","year":"1991","journal-title":"Bone Marrow Transplantation"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib93","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib94","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V84.5.1603.bloodjournal8451603","article-title":"Immunophenotype of adult acute lymphoblastic leukemia, clinical\u00a0parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia","volume":"84","author":"Boucheix","year":"1994","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2006.10.003_bib95","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib96","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJM199808273390904","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2013Childhood Leukemia Cooperative Group","volume":"339","author":"Cave","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib97","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1182\/blood.V87.12.5251.bloodjournal87125251","article-title":"Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia","volume":"87","author":"Brisco","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib98","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V99.3.863","article-title":"Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study","volume":"99","author":"Annino","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib99","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/sj.leu.2400841","article-title":"Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response","volume":"11","author":"Foroni","year":"1997","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib100","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib101","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00062752-200311000-00011","article-title":"Acute lymphocytic leukemia: role of hematopoietic stem cell transplantation in current management","volume":"10","author":"Avivi","year":"2003","journal-title":"Current Opinion in Hematology"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib102","first-page":"1346","article-title":"Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial","volume":"90","author":"Ribera","year":"2005","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib103","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.1994.12.12.2580","article-title":"Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia","volume":"12","author":"Sebban","year":"1994","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib104","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0889-8588(05)70190-8","article-title":"Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87","volume":"14","author":"Thiebaut","year":"2000","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib105","first-page":"1687","article-title":"HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission","volume":"10","author":"Gale","year":"1996","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib106","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib107","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ajh.2830450413","article-title":"Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults","volume":"45","author":"Welborn","year":"1994","journal-title":"American Journal of Hematology"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib108","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0889-8588(05)70204-5","article-title":"Salvage therapy for refractory or relapsed acute lymphocytic leukemia","volume":"15","author":"Garcia-Manero","year":"2001","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib109","first-page":"145","article-title":"GIMEMA","volume":"89","author":"Camera","year":"2004","journal-title":"Haematologica"},{"issue":"supplement 2","key":"10.1016\/j.beha.2006.10.003_bib110","first-page":"196","article-title":"Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: a report from the IBMTR. The International Bone Marrow Transplant Registry","volume":"6","author":"Bortin","year":"1992","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.beha.2006.10.003_bib111","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"18","key":"10.1016\/j.beha.2006.10.003_bib112","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"The New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib113","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib114","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1182\/blood.V88.12.4711.bloodjournal88124711","article-title":"Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation","volume":"88","author":"Bjorkstrand","year":"1996","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2006.10.003_bib115","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1182\/blood.V88.7.2787.bloodjournal8872787","article-title":"Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome","volume":"88","author":"Bensinger","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u20138 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib117","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"issue":"9023","key":"10.1016\/j.beha.2006.10.003_bib118","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(05)64525-4","article-title":"Graft-versus-myeloma effect","volume":"348","author":"Aschan","year":"1996","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib119","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib120","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1182\/blood.V90.10.4206","article-title":"Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation","volume":"90","author":"Lokhorst","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib121","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bmt.1701546","article-title":"Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation","volume":"23","author":"van der","year":"1999","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib122","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1182\/blood.V97.9.2574","article-title":"High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions","volume":"97","author":"Badros","year":"2001","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2006.10.003_bib123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1200\/JCO.20.5.1295","article-title":"Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning","volume":"20","author":"Badros","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib124","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2002-04-1150","article-title":"Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality","volume":"100","author":"Kroger","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib125","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib126","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0301-472X(02)01010-X","article-title":"Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning","volume":"31","author":"Lee","year":"2003","journal-title":"Experimental Hematology"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib127","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2004.06.002","article-title":"Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan\/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma","volume":"10","author":"Kroger","year":"2004","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/bbmt.2003.50009","article-title":"Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity","volume":"9","author":"Peggs","year":"2003","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"11","key":"10.1016\/j.beha.2006.10.003_bib129","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib130","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2006.10.003_bib131","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib132","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/sj.bmt.1704483","article-title":"Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma","volume":"33","author":"Popat","year":"2004","journal-title":"Bone Marrow Transplantation"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib133","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/sj.bmt.1704508","article-title":"Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy","volume":"33","author":"Czyz","year":"2004","journal-title":"Bone Marrow Transplantation"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib134","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/annonc\/mdf228","article-title":"The International Prognostic Factors Project score for advanced Hodgkin's disease is useful for predicting outcome of autologous hematopoietic stem cell transplantation","volume":"13","author":"Bierman","year":"2002","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.20.1.221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group","volume":"20","author":"Josting","year":"2002","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib136","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib137","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.bbmt.2006.03.013","article-title":"Reduced intensity conditioning for allogeneic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: where do we stand?","volume":"12","author":"Anderlini","year":"2006","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"9475","key":"10.1016\/j.beha.2006.10.003_bib138","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib139","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.bmt.1704942","article-title":"Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen","volume":"35","author":"Anderlini","year":"2005","journal-title":"Bone Marrow Transplantation"},{"issue":"6","key":"10.1016\/j.beha.2006.10.003_bib140","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2141.2005.05388.x","article-title":"Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions","volume":"128","author":"Hart","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"23","key":"10.1016\/j.beha.2006.10.003_bib141","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.beha.2006.10.003_bib142","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Haioun","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib143","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1200\/JCO.1998.16.8.2796","article-title":"VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group","volume":"16","author":"Santini","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.beha.2006.10.003_bib144","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJM199504203321601","article-title":"Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma","volume":"332","author":"Verdonck","year":"1995","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.beha.2006.10.003_bib145","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1200\/JCO.1996.14.2.534","volume":"14","author":"Martelli","year":"1996","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib146","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1182\/blood-2004-01-0231","article-title":"Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry","volume":"104","author":"Freytes","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2006.10.003_bib147","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/sj.bmt.1702625","article-title":"Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy. Ontario BMT Network, Canada","volume":"26","author":"Schimmer","year":"2000","journal-title":"Bone Marrow Transplantation"},{"issue":"13","key":"10.1016\/j.beha.2006.10.003_bib148","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.beha.2006.10.003_bib149","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.beha.2006.10.003_bib150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2006.10.003_bib151","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biology of Blood and Marrow Transplantation"},{"issue":"12","key":"10.1016\/j.beha.2006.10.003_bib152","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2006.10.003_bib153","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2006.10.003_bib154","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood.V98.13.3595","article-title":"Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality","volume":"98","author":"Khouri","year":"2001","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692606000727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T13:17:13Z","timestamp":1587475033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692606000727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,6]]},"references-count":154,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,6]]}},"alternative-id":["S1521692606000727"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2006.10.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2007,6]]}}}